Genflow Seeks Investors for Novel SIRT6 DNA Repair Anti-Ageing Therapy
Great to see a startup willing to explicitly state they are treating ageing itself as a disease
Join the club for FREE to access the whole archive and other member benefits.
CEO of Genflow Biosciences and Executive Chairman of Immunethep
A wide range of leading positions in pharmaceutical and biotech companies, including Immunethep, DanDrit/Enochian, Pfizer, Schering Plough, Pharmacia and BioStrategies.
Also a Non Executive Director at Novicol International Holding Inc
Early academic experience includes Research Associate at the Harvard AIDS Institute.
Visit website: https://genflowbio.com/leadership/#eric
See also: Genflow Biosciences - Developing medicines that potentially halt, slow or reverse the aging process
Details last updated 13-Jul-2020
Great to see a startup willing to explicitly state they are treating ageing itself as a disease
Company aims to target age-related diseases and liver disease NASH
Currently exploring the SIRT6 potential with University of Rochester’s Aging Research Center
Seeking funds to develop gene therapies that target ageing in humans and dogs
Novel gene therapies to prevent the accelerated aging process